StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) income statement

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$398.08−23.91 (-5.67%)

Close on Nov 18, 2026Market cap $9.20BP/E –Yield –

Madrigal Pharmaceuticals, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-25.1%
Net margin
-25.3%
Return on equity, FY2025
-42.5%

Financial strength

Current ratio
3.20
Debt to equity
0.65
Debt to assets
27.4%
Cash to current liabilities
78.2%

Valuation

P/E ratio
–
Price to sales
7.16
Price to book
17.56
Dividend yield
–

See a number that looks wrong?